SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03012386

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Role of CD36 in Nutrient Delivery and Its Dysfunction in African Americans

This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose uptake in CD36 rs3211938 G-allele carriers.

NCT03012386 Insulin Resistance Endothelial Dysfunction
MeSH: Insulin Resistance
HPO: Insulin resistance

1 Interventions

Name: Sildenafil Citrate

Description: phosphodiesterase 5 inhibitor

Type: Drug

Sildenafil citrate


Primary Outcomes

Description: The primary endpoint is the change in microvascular blood volume (ΔMBV) during insulin infusion from baseline, an index of insulin-stimulated microvascular recruitment.

Measure: insulin-stimulated microvascular recruitment.

Time: 4 weeks

Secondary Outcomes

Description: Glucose infusion rate during hyperinsulinemic euglycemic clamp

Measure: Insulin sensitivity

Time: 4 weeks

Purpose: Basic Science

Single Group Assignment


There is one SNP

SNPs


1 rs3211938

CD36 in Nutrient Delivery and Its Dysfunction This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose uptake in CD36 rs3211938 G-allele carriers.

- Hematocrit < 34% - Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult - Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month) - History of alcohol or drug abuse - Treatment with any investigational drug in the one month preceding the study - Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study - Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, unlikelihood of completing the study, and investigator discretion Insulin Resistance Endothelial Dysfunction Insulin Resistance Subjects carrying the G-allele of CD36 coding SNP rs3211938 that results in 50% reduction of CD36 levels in ~25% of African Americans have endothelial dysfunction.



HPO Nodes


HPO:
Insulin resistance
Genes 56
BLK PPP1R3A KLF11 HNF1A HNF1B IGF1 LIPE NEUROD1 IGFALS ZMPSTE24 SLC12A3 CEL LMNA ALMS1 CLCNKB PTF1A INS PIK3R1 POLD1 FOS ABCC8 CYP19A1 CIDEC KCNJ11 AGPAT2 INSR ZFP57 WRN DCAF17 GATA6 PDX1 MFN2 APPL1 PLAGL1 AKT2 CAVIN1 BSCL2 HSD3B2 DBH GCK LMNB2 PAX4 CAV1 HSD11B1 PPARG XRCC4 NSMCE2 PLIN1 HNF4A HYMAI EIF2AK3 LEP LEPR STAT3 CEP19 PMM2